Cell therapy biotech nabs Series A; Metagenome startup snags $77M round
A cancer cell therapy biotech has reeled in about $20 million to push forward its ongoing Phase I.
Alloplex Biotherapeutics has secured about $20 million of an estimated $25 million round, per SEC paperwork. CEO Frank Borriello posted to LinkedIn two months ago noting the company would look to close a Series A by Jan. 27. Borriello, a former VP at Baxalta, formed the US-Australian biotech in 2016.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.